Industry news round-up: updates from June 2025
Explore the latest advancements in real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) as featured on The Evidence Base during June 2025.
The Crohn’s & Colitis Foundation and PhaseV have announced a new partnership to enhance clinical trial design and execution for inflammatory bowel disease (IBD) through the use of advanced AI and RWD analytics. The collaboration is intended to support more flexible, data-driven approaches that better reflect the complexity of IBD and improve treatment development.
Trinity Life Sciences has announced a new partnership with Ontada aimed at improving commercial decision-making in community oncology. The collaboration combines advanced analytics with RWD to support forecasting, patient and provider insights, and strategy development across the product lifecycle.
Newcastle upon Tyne Hospitals NHS Foundation Trust has entered into partnerships with Flatiron Health UK and Promptly Health to enhance the use of RWD for clinical research, innovation, and improved healthcare delivery.
A new partnership between Iris Telehealth and Holmusk combines RWD with AI-powered analytics to support value-based care and improve mental health outcomes across local healthcare markets.
HealthVerity and Medeloop have announced a new partnership aimed at simplifying and accelerating the analysis of RWD, supporting faster and more actionable insights across healthcare and life sciences.
The collaboration will convert one of the world’s largest biobank collections into harmonized, multimodal datasets to support AI-driven precision medicine, translational research, and diagnostic development.
The alliance will integrate AI-powered data intelligence and federated evidence networks to accelerate RWE generation and support improved patient outcomes.
FDA leaders outline vision for advancing US healthcare through big data, AI and drug pricing reform
FDA Commissioner Marty Makary and CBER Director Vinay Prasad outline strategic priorities for strengthening the US healthcare system, emphasizing the role of RWD, AI, and pricing reform to improve outcomes and support innovation.
FDA publishes latest data on RWE use in drug and biologic submissions
A year-on-year comparison shows increased uptake of RWE protocols, particularly in biologics, and the growing use of observational studies in postmarketing commitments.
The long-term partnership will generate regulatory-grade RWD to support precision medicine, accelerate access to innovative therapies, and strengthen a UK-wide research infrastructure.
Atropos Health and Kythera Labs to accelerate oncology research with RWD
Following a series of recent developments, Atropos Health has entered into a multi-year agreement with Kythera Labs to enhance oncology research and care by expanding access to high-quality RWD through the Atropos Evidence Network.
RWD study shows bariatric surgery leads to significantly greater weight loss than GLP-1 drugs
A new real-world study conducted by researchers from NYU Langone Health and NYC Health + Hospitals has found that bariatric surgery resulted in five-times more weight loss than GLP-1 drugs over 2 years, highlighting the need to reassess treatment expectations and strategies.
FDA and NIH publish unified glossary to strengthen real-world evidence research
The FDA and NIH have jointly released a standardized glossary of RWD and RWE terms to improve communication and consistency across clinical studies involving innovative designs and data sources.
UK study to investigate genetic risk of acute pancreatitis from GLP-1 medicines
The Yellow Card Biobank has launched a new research initiative to examine whether genetic factors contribute to the risk of acute pancreatitis in patients taking GLP-1 receptor agonists, including Ozempic, Mounjaro, and Wegovy, for the treatment of Type 2 diabetes or weight management.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |